These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3875038)

  • 1. PKA contamination of immunoglobulin G.
    Eibl MM
    N Engl J Med; 1985 Aug; 313(9):581. PubMed ID: 3875038
    [No Abstract]   [Full Text] [Related]  

  • 2. Prekallikrein activator in human albumin.
    Paton CJ; Kerry PJ
    Lancet; 1981 Oct; 2(8249):747. PubMed ID: 6116876
    [No Abstract]   [Full Text] [Related]  

  • 3. The assay of prekallikrein activator in human blood products.
    Snape TJ; Griffith D; Vallet L; Wesley ED
    Dev Biol Stand; 1979; 44():115-20. PubMed ID: 317467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro assay for prekallikrein activator (PKA).
    Lundblad JL
    Dev Biol Stand; 1979; 44():107-14. PubMed ID: 317466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bradykinin-mediated hypotension after infusion of plasma-protein fraction.
    Van Rosevelt RF; Bakker JC; Sinclair DM; Damen J; Van Mourik JA
    J Lab Clin Med; 1982 Aug; 100(2):288-95. PubMed ID: 6980251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a bradykinin-generating hypotensive substance in plasma protein fraction: prekallikrein activator (PKA-beta-Xiia).
    Bakker JC; de Vries-van Rossen A; Radema H; Bleeker W; Ufkes JG; van Rosevelt RF; van Mourik JA
    Adv Exp Med Biol; 1983; 156 (Pt B)():1091-7. PubMed ID: 6602466
    [No Abstract]   [Full Text] [Related]  

  • 7. Direct assay of factor XIIa in plasma with synthetic chromogenic substrates.
    Kluft C; Svendsen L; Los P
    Adv Exp Med Biol; 1983; 156():201-4. PubMed ID: 6190367
    [No Abstract]   [Full Text] [Related]  

  • 8. Standardization of prekallikrein activator (PKA): the 1st British reference preparation for PKA.
    Kerry PJ; Curtis AD; Paton CJ; Thomas DP
    Br J Haematol; 1982 Oct; 52(2):275-81. PubMed ID: 6982063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable plasma protein solution. Modern preparation methods reduce risk of untoward reactions.
    Schiff P
    Med J Aust; 1982 Jun; 1(12):493. PubMed ID: 6980365
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative studies of impurities in intravenous immunoglobulin preparations.
    Lundblad JL; Mitra G; Sternberg MM; Schroeder DD
    Rev Infect Dis; 1986; 8 Suppl 4():S382-90. PubMed ID: 3092304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contact activation patterns of human plasma measured with a fluorogenic substrate.
    Dooijewaard G; Kluft C
    Adv Exp Med Biol; 1983; 156():115-20. PubMed ID: 6602460
    [No Abstract]   [Full Text] [Related]  

  • 12. Prekallikrein activator levels and side effects with human albumin preparations.
    Lüben G; Quast U; Geiger H
    Dev Biol Stand; 1980; 48():123-7. PubMed ID: 6974110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The cause of the secondary reaction in the intravenous use of administered immunoglobulin].
    Geursen RG; Kroh U; Krump W; Scharfe B
    Beitr Infusionther Klin Ernahr; 1982; 9():95-114. PubMed ID: 6756385
    [No Abstract]   [Full Text] [Related]  

  • 14. Structural and functional characterization of factor XII.
    Tans G; Rosing J
    Semin Thromb Hemost; 1987 Jan; 13(1):1-14. PubMed ID: 3551074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluid phase activation of Hageman factor (factor XII) in citrated human plasma by bromelain: an application to the indirect enzymatic assay for Hageman factor.
    Oh-ishi S
    Thromb Res; 1982 Sep; 27(5):619-23. PubMed ID: 6983741
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content.
    Römer J; Morgenthaler JJ; Scherz R; Skvaril F
    Vox Sang; 1982 Feb; 42(2):62-73. PubMed ID: 6977944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypotensive effect of prekallikrein activator (PKA) in plasma protein fraction (PPF).
    Heinonen J; Peltola K; Himberg JJ; Suomela H
    Dev Biol Stand; 1980; 48():129-30. PubMed ID: 7024018
    [No Abstract]   [Full Text] [Related]  

  • 18. [Determination of plasma prekallikrein using beta-XIIa (Hageman factor fragment)].
    Komiyama Y; Egawa H; Murata K
    Rinsho Byori; 1984 May; 32(5):558-62. PubMed ID: 6332927
    [No Abstract]   [Full Text] [Related]  

  • 19. Prekallikrein activator.
    Gallimore MJ; Friberger P
    Thromb Haemost; 1984 Dec; 52(3):366. PubMed ID: 6335791
    [No Abstract]   [Full Text] [Related]  

  • 20. [Study and clinical significance of the fibrinolysis component dependent on factor XIIa].
    Arkhipov AG; Eremin GF
    Lab Delo; 1985; (11):648-51. PubMed ID: 2417013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.